Deimmunizing A Big Antibiotic | Chemical & Engineering News
Volume 93 Issue 26 | p. 22 | Concentrates
Issue Date: June 29, 2015

Deimmunizing A Big Antibiotic

Drug Discovery: Engineered antibacterial enzyme holds promise for inciting less severe immune response when treating MRSA infections
By Judith Lavelle
Department: Science & Technology
News Channels: Biological SCENE
Keywords: MRSA, antibiotic, biotherapy, immunology
[+]Enlarge
Lysostaphin has been shown to eliminate MRSA, depicted here in an artist’s rendering.
Credit: Shutterstock
Rendering of methicillin-resistant Staphylococcus aureus.
 
Lysostaphin has been shown to eliminate MRSA, depicted here in an artist’s rendering.
Credit: Shutterstock
[+]Enlarge
The remaining T-cell epitopes of the Lib5 variant of lysostaphin are highlighted in red.
Credit: Chem. Biol.
Lysostaphin variant Lib5 developed by Dartmouth researchers.
 
The remaining T-cell epitopes of the Lib5 variant of lysostaphin are highlighted in red.
Credit: Chem. Biol.

As fewer and fewer small-molecule antibiotics remain effective against drug-resistant bacteria, some researchers are turning to antibacterial enzymes to combat resilient infections. But many of these large-molecule drug candidates are intercepted by the host’s immune system before they can cure the illness. Now, researchers at Dartmouth College led by protein engineer Karl E. Griswold have shown that an engineered variant of one such enzyme, lysostaphin, may treat methicillin-resistant Staphylococcus aureus (MRSA) infections more effectively than a nonengineered version (Chem. Biol. 2015, DOI: 10.1016/j.chembiol.​2015.04.017). The group deimmunized lysostaphin by first using a predictive algorithm to identify the protein’s T-cell epitopes—regions of the enzyme that the immune system recognizes. These epitopes would bind to a cell receptor coded for by a specific HLA allele. The researchers then screened a library of epitope-depleted lysostaphin variants to identify a candidate that would have low immunogenicity but still maintain the protein’s powerful lysing function. Genetically humanized mice given the screen’s best result, dubbed Lib5, were more likely to survive a MRSA infection than those given wild-type lysostaphin. The next step, Griswold says, will be to completely deimmunize lysostaphin against multiple HLA alleles.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment